Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-010 in Healthy Participants
NCT06356259Phase 1Terminated
- Sponsor
- ImmunoRx Pharma
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IRX-010 in ulcerative colitis (UC), rheumatoid arthritis (RA) and Crohn's disease (4 arms), sponsored by ImmunoRx Pharma. Primary endpoints: Serious Adverse Events at Day 168 and Treatment-Emergent Adverse Events at Day 168. Started Jun 2023; status: terminated.
02
Drugs
IRX-010
03
Conditions
ulcerative colitis (UC)rheumatoid arthritis (RA)Crohn's disease
Beyond the preview
Go deeper on NCT06356259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356259.